Update on rescue therapies in patients with lamivudine-resistant chronic hepatitis B

Drug Design, Development and Therapy

Volumn 7, Issue , 2013, Pages 777-788

  Chao, Daniel C ^a   Hu, Ke Qin ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adefovir; Anti viral resistance; Chronic hepatitis B; Entecavir; Lamivudine; Nucleot(s)ide analogs; Tenofovir

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ALPHA FETOPROTEIN; EMTRICITABINE; ENTECAVIR; HEPATITIS B ANTIBODY; HEPATITIS B(E) ANTIGEN; IMMUNOSUPPRESSIVE AGENT; LAMIVUDINE; TELBIVUDINE; TENOFOVIR; VIRUS DNA;

ADD ON THERAPY; CLINICAL FEATURE; DECOMPENSATED LIVER CIRRHOSIS; DISEASE COURSE; DISEASE EXACERBATION; DRUG COST; DRUG MEGADOSE; DRUG POTENCY; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; GENE MUTATION; GENOTYPE; HEALTH CARE ACCESS; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LABORATORY TEST; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MIXED INFECTION; MONOTHERAPY; MORTALITY; NONHUMAN; PATIENT COMPLIANCE; PATIENT EDUCATION; POPULATION RESEARCH; PRESCRIPTION; RECOMMENDED DRUG DOSE; RECURRENT DISEASE; REINFECTION; REVIEW; RISK FACTOR; RISK REDUCTION; SEROCONVERSION; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS INHIBITION; VIRUS LOAD; VIRUS REPLICATION; WORLD HEALTH ORGANIZATION;

ADEFOVIR; ANTI-VIRAL RESISTANCE; CHRONIC HEPATITIS B; ENTECAVIR; LAMIVUDINE; NUCLEOT(S)IDE ANALOGS; TENOFOVIR;

ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; SALVAGE THERAPY;

EID: 84882777679     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S33947     Document Type: Review

References (63)

1. cdc.gov [homepage on the Internet]. Hepatitis B frequently asked questions for the public. Centers for Disease Control; 2008 [updated June 9, 2009; cited January 1, 2013]. Available from: http://www.cdc.gov/hepatitis/b/bFAQ.htm#statistics. Accessed January 1, 2013.
2. http://www.who.int/en/ [homepage on the Internet]. Hepatitis B fact sheet. World Health Organization; 2012 [cited January 1, 2013]. Available from: http://www.who.int/mediacentre/factsheets/fs204/en/. Accessed January 1, 2013.
3. Lok AS, McMahon BJ. American Association for the Study of Liver Diseases (AASLD) Practice Guidelines for Management of Chronic Hepatitis B: Update 2009. Hepatology. 2009. Available from: http://www. aasld.org/practiceguidelines/documents/bookmarked%20practice%20 guidelines/chronic_hep_b_update_2009%208_24_2009.pdf. Accessed January 1, 2013.
4. Schütte K, Bornschein J, Malfertheiner P. Hepatocellular carcinoma - epidemiological trends and risk factors. Dig Dis. 2009;27(2):80-92.
5. Wong DK, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med. 1993;119(4):312-323.
6. Yuen MF, Lai CL. Treatment of chronic hepatitis B: Evolution over two decades. J Gastroenterol Hepatol. 2011;26 Suppl 1:138-143.
7. Lai CL, Chien RN, Leung NW, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med. 1998;339(2):61-68.
8. Chang TT, Gish RG, de Man R et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med. 2006;354(10):1001-1010.
9. Lok AS, Lai CL, Leung N, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology. 2003;125(6):1714-1722.
10. Tenney DJ, Rose RE, Baldick CJ, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy. Hepatology. 2009;49(5):1503-1514.
11. Liaw YF, Leung N, Kao JH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int. 2008;2(3):263-283.
12. Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med. 1999;341(17):1256-1263.
13. Zoulim F. Hepatitis B virus resistance to antiviral drugs: where are we going? Liver Int. 2011;31 Suppl 1:111-116.
14. Fung J, Lai CL, Seto WK, Yuen MF. Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B. J Antimicrob Chemother. 2011;66(12):2715-2725.
15. Yuen MF, Sablon E, Hui CK, Yuan HJ, Decraemer H, Lai CL. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology. 2001;34(4 Pt 1): 785-791.
16. Fournier C, Zoulim F. Antiviral therapy of chronic hepatitis B: prevention of drug resistance. Clin Liver Dis. 2007;11(4):869-892ix.
17. Wang C, Fan R, Sun J, Hou J. Prevention and management of drug resistant hepatitis B virus infections. J Gastroenterol Hepatol. 2012;27(9):1432-1440.
18. Marcellin P, Sung J, Piratvisuth T. Avoiding and managing lamivudine resistance in chronic hepatitis B: current approaches and potential strategies including pegylated interferon. Liver Int. 2010;30(5): 657-668.
19. Lai CL, Gane E, LiawYF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med. 2007;357(25):2576-2588.
20. Gane EJ. The Roadmap concept: using early on-treatment virologic responses to optimize long-term outcomes for patients with chronic hepatitis B. Hepatol Int. 2008;2(3):304-307.
21. Hsieh TH, Tseng TC, Liu CJ, et al. Hepatitis B virus genotype B has an earlier emergence of lamivudine resistance than genotype C. Antivir Ther (Lond). 2009;14(8):1157-1163.
22. Mello FC, Fernandes CA, Gomes Sde A. Antiviral therapy against chronic hepatitis B in Brazil: high rates of lamivudine resistance mutations and correlation with HBV genotypes. Mem Inst Oswaldo Cruz. 2012;107(3):317-325.
23. Benhamou Y, Bochet M, Thibault V, et al. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology. 1999;30(5):1302-1306.
24. Kosi L, Reiberger T, Payer BA, et al. Five-year on-treatment efficacy of lamivudine-, tenofovir- and tenofovir + emtricitabine-based HAART in HBV-HIV-coinfected patients. J Viral Hepat. 2012;19(11):801-810.
25. Sueki R, Maekawa S, Miura M, et al. Correlation between pretreatment viral sequences and the emergence of lamivudine resistance in hepatitis B virus infection. J Med Virol. 2012;84(9):1360-1368.
26. Chen CH, Lee CM, Tung WC, et al. Evolution of full-length HBV sequences in chronic hepatitis B patients with sequential lamivudine and adefovir dipivoxil resistance. J Hepatol. 2010;52(4):478-485.
27. Zhao J, Guo Y, Yan Z, Liang P, Zhang J, Liu Y. The natural YMDD mutations of hepatitis B virus in Western China. Scand J Infect Dis. 2012;44(1):44-47.
28. Tan YW, Ge GH, Zhao W, et al. YMDD motif mutations in chronic hepatitis B antiviral treatment naïve patients: a multi-center study. Braz J Infect Dis. 2012;16(3):250-255.
29. Tan Y, Ding K, Su J, et al. The naturally occurring YMDD mutation among patients chronically infected HBV and untreated with lamivudine: a systematic review and meta-analysis. PLoS ONE. 2012;7(3):e32789.
30. Lee SH, Kim HS, Byun IS, et al. Pre-existing YMDD mutants in treatment-naïve patients with chronic hepatitis B are not selected during lamivudine therapy. J Med Virol. 2012;84(2):217-222.
31. Thai H, Campo DS, Lara J, et al. Convergence and coevolution of hepatitis B virus drug resistance. Nat Commun. 2012;3:789.
32. Svicher V, Cento V, Salpini R, et al. Role of hepatitis B virus genetic barrier in drug-resistance and immune-escape development. Dig Liver Dis. 2011;43(12):975-983.
33. Margeridon-Thermet S, Shulman NS, Ahmed A, et al. Ultra-deep pyrosequencing of hepatitis B virus quasispecies from nucleoside and nucleotide reverse-transcriptase inhibitor (NRTI)-treated patients and NRTI-naive patients. J Infect Dis. 2009;199(9):1275-1285.
34. Solmone M, Vincenti D, Prosperi MC, Bruselles A, Ippolito G, Capobianchi MR. Use of massively parallel ultradeep pyrosequencing to characterize the genetic diversity of hepatitis B virus in drug-resistant and drug-naive patients and to detect minor variants in reverse transcriptase and hepatitis B S antigen. J Virol. 2009;83(4):1718-1726.
35. European Association for the Study of the Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol. 2012;57(1):167-185.
36. Papatheodoridis GV, Cholongitas E, Archimandritis AJ, Burroughs AK. Current management of hepatitis B virus infection before and after liver transplantation. Liver Int. 2009;29(9):1294-1305.
37. Buchanan C, Tran TT. Current status of liver transplantation for hepatitis B virus. Clin Liver Dis. 2011;15(4):753-764.
38. Rapti IN, Hadziyannis SJ. Treatment of special populations with chronic hepatitis B infection. Expert Rev Gastroenterol Hepatol. 2011;5(3):323-339.
39. Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X. Interventions for enhancing medication adherence [review]. Cochrane Database Syst Rev. 2008;2:CD000011.
40. Bonner JE, Barritt AS, Fried MW, Evon DM. Tangible resources for preparing patients for antiviral therapy for chronic hepatitis C. Dig Dis Sci. 2012;57(6):1439-1444.
41. Fan XH, Geng JZ, Wang LF, et al. De novo combination therapy with lamivudine and adefovir dipivoxil in chronic hepatitis B patients. World J Gastroenterol. 2011;17(43):4804-4809.
42. Wang LC, Chen EQ, Cao J, et al. De novo combination of lamivudine and adefovir versus entecavir monotherapy for the treatment of naïve HBeAg-negative chronic hepatitis B patients. Hepatol Int. 2011;5(2): 671-676.
43. Perrillo R, Hann HW, Mutimer D, et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B withYMDD mutant hepatitis B virus. Gastroenterology. 2004;126(1):81-90.
44. Perrillo RP, Hann HW, Schiff E, et al. Extended treatment with lamivudine and adefovir dipivoxil in chronic hepatitis B patients with lamivudine resistance. Hepatol Int. 2011;5(2):654-663.
45. Sung JJ, Lai JY, Zeuzem S, et al. Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B. J Hepatol. 2008;48(5):728-735.
46. Rapti I, Dimou E, Mitsoula P, Hadziyannis SJ. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology. 2007;45(2):307-313.
47. Zhao P, Wang C, Huang L, Xu D, Li T. Comparison of rescue strategies in lamivudine-resistant patients with chronic hepatitis B. Antiviral Res. 2012;96(2):100-104.
48. Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2006;354(10):1011-1020.
49. Sherman M, Yurdaydin C, Sollano J, et al. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology. 2006;130(7):2039-2049.
50. Sherman M, Yurdaydin C, Simsek H, et al. Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks. Hepatology. 2008;48(1):99-108.
51. Kim HJ, Park JH, Park DI, et al. Rescue therapy for lamivudine-resistant chronic hepatitis B: comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy. J Gastroenterol Hepatol. 2010;25(8):1374-1380.
52. Ryu HJ, Lee JM, Ahn SH, et al. Efficacy of adefovir add-on lamivudine rescue therapy compared with switching to entecavir monotherapy in patients with lamivudine-resistant chronic hepatitis B. J Med Virol. 2010;82(11):1835-1842.
53. Sheng YJ, Liu JY, Tong SW, et al. Lamivudine plus adefovir combination therapy versus entecavir monotherapy for lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysis. Virol J. 2011;8:393.
54. Ha M, Zhang G, Diao S, et al. Rescue therapy for lamivudine-resistant chronic hepatitis B: adefovir monotherapy, adefovir plus lamivudine or entecavir combination therapy. Intern Med. 2012;51(12):1509-1515.
55. LimYS, Lee JY, Lee Dx, /xetalet al/etal. Randomized trial of entecavir plus adefovir in patients with lamivudine-resistant chronic hepatitis B who show suboptimal response to lamivudine plus adefovir. Antimicrob Agents Chemother. 2012;56(6):2941-2947.
56. Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med. 2008;359(23):2442-2455.
57. van Bömmel F de Man RA, Wedemeyer H et al. Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology. 2010;51(1):73-80.
58. van Bömmel F, Wünsche T, Mauss S, et al. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology. 2004;40(6):1421-1425.
59. Ong A, Wong VW, Wong GL, Chan HY, Tse CH, Chan HL. Management options for lamivudine-resistant chronic hepatitis B patients with suboptimal virological suppression by adefovir. Aliment Pharmacol Ther. 2011;34(8):972-981.
60. Allen MI, Deslauriers M, Andrews CW, et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology. 1998;27(6): 1670-1677.
61. Tenney DJ, Levine SM, Rose RE, et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine. Antimicrob Agents Chemother. 2004;48(9):3498-3507.
62. Lai CL, Leung N, Teo EK, et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology. 2005;129(2):528-536.
63. Locarnini S, Hatzakis A, Heathcote J, et al. Management of antiviral resistance in patients with chronic hepatitis B. Antivir Ther (Lond). 2004;9(5):679-693.